Primary Outcome Measures Compliance of ERAS® guidelines [ Time Frame: 3 months ] Post-ERAS® implementation phase: compliance rate towards the relevant core items from ERAS guidelines Secondary Outcome Measures Acceptance and feasibility of ERAS® guidelines [ Time Frame: 3 months ] Pre-ERAS® phase (current clinical practice): current compliance rate towards the ERAS guidelines Inclusion Criteria Adults female and[…]
Mesothelioma
A Virus that Affects Goats Could Help Treat Mesothelioma
Mesothelioma, a cancer of the membrane that surrounds the lungs, abdomen, heart, and testicles is a very aggressive cancer. It spreads very quickly and when the tumors grow big enough, they crowd out organs and make it hard for people to breath. Mesothelioma sufferers can experience coughing, chest pain, and[…]
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Primary Outcome Measures ORR [ Time Frame: 6 months after the final enrollment ] Objective Response Rate（ORR）according to mRECIST 1.1 standard Secondary Outcome Measures DOR [ Time Frame: 24 months ] Duration of remission DCR [ Time Frame: 24 months ] Disease Control Rate PFS [ Time Frame: 24 months ] Progression Free Survival OS [ Time Frame: 24 months ] Overall Survival AE [ Time Frame: 24 months ] Adverse event SAE [ Time Frame: 24[…]
Epigenetics Used to Improve Immunotherapy for Mesothelioma
Researchers are looking into changing mesothelioma cells to make them more susceptible to immunotherapy. Mesothelioma is a hard cancer to treat, so new approaches need to be developed to try to lengthen and improve mesothelioma patients’ lives. Immunotherapy can work well for some, but for others it does very little,[…]
LMB-100 and Ipilumab Combination Being Tested for Pleural and Peritoneal Mesothelioma
The National Cancer Institute just started a study to see if it could make immunotherapy more potent for treating mesothelioma. The study combines a manmade protein that kills cancer cells called LMB-100 and an immunotherapy drug called ipilumab. The problem with current immunotherapy treatments is they do not work well[…]
GPX-1 Could be used as a Biomarker for Mesothelioma
An enzyme that helps clean up the byproducts of cellular oxidation could potentially be a biomarker for pleural mesothelioma. People with very small amounts of the enzyme were found to survive longer than people who have higher levels of the enzyme. The enzyme is Glutathione peroxidase-1 (GPX-1). It can be[…]
UCARTMESO CAR-T Cell Therapy Can Help Kill Mesothelioma Cells
A new treatment utilizing CAR-T cell therapy could help prevent mesothelioma cells from protecting themselves. The treatment, called UCARTMESO, is being developed by the French biopharmaceutical company Cellectis. The treatment works by targeting cells that overexpress mesothelin, which is an antigen that prevents cells from sending immune suppressive signals. A[…]
Follow Up Care for Mesothelioma
Follow-up care is crucial for treating mesothelioma patients. A study out of the United Kingdom found that when patients receive follow-up care, more input from their caregivers, continuity, and more timely information was necessary. The study involved three National Health Service facilities in England. Two of the centers were secondary[…]
Quinacrine Combined with Cisplatin Can Help Fight Mesothelioma Cancer Cells
Mesothelioma patients with a gene mutation could benefit greatly from using an anti-malaria drug called quinacrine. Quinacrine is known by the brand name Atabrine. For a long time, it was the primary anti-malaria drug, but it has been replaced by the preferred chloroquine. Researchers at Penn State found that quinacrine[…]
Patients with Mesothelioma Don’t Always Have Access to the Best Care
Unfortunately, there is a lack of equality when it comes to treating mesothelioma patients because access to care can be very inconsistent. Patients might not have access to a high-volume academic hospital that treats mesothelioma patients, so they are not receiving the proper care that some people might receive. Patients[…]
Skip to content